{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:06Z","timestamp":1792269486746,"version":"4.4.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We present the case of a 69-year-old male patient with locally advanced squamous cell carcinoma (SCC) of the root of the tongue, who was enrolled in the clinical trial \u2018prospective clinical study of envafolimab combined with neoadjuvant chemotherapy and transformation therapy for head and neck SCC.\u2019 After three cycles of envafolimab combined with chemotherapy, the tumor completely subsided, achieving complete remission as confirmed by re-examination through neck enhanced computed tomography and electronic nasopharyngolaryngoscopy. The patient was subsequently treated with envafolimab alone, achieving a progression-free survival of more than 20 months to date. During maintenance treatment, the patient developed adrenocortical dysfunction induced by immune checkpoint inhibitors, which improved after symptomatic treatment and did not affect the patient\u2019s quality of life. This article is the first to report the use of a new immune checkpoint inhibitor for SCC of the root of the tongue, achieving clinical cure.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_2290_25","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:00:08Z","timestamp":1790766008000},"page":"767-770","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Complete clinical remission of squamous cell carcinoma of the root of the tongue following treatment with envafolimab in combination with neoadjuvant chemotherapy: A case report"],"prefix":"10.4103","volume":"22","author":[{"given":"Lu","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"},{"name":"Department of Otorhinolaryngology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"},{"name":"Department of Otorhinolaryngology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"R1-20261016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4103\/jcrt.jcrt_201_25","article-title":"A correlation of worst pattern of invasion (WPOI) and tumor budding (TB) with clinicopathological factors in oral squamous cell carcinoma (OSCC)","volume":"21","author":"Singh","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4103\/jcrt.jcrt_2510_24","article-title":"Phase-II randomized study of carboplatin plus capecitabine versus 3-weekly cisplatin in locally advanced head-and-neck cancer patients undergoing concurrent chemoradiation (CARCAP-HN)","volume":"21","author":"Mohanty","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+oropharyngeal cancer","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2017.76.8770","article-title":"Tumor mutation burden: Leading immunotherapy to the era of precision medicine?","volume":"36","author":"Steuer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41588-024-02039-4","article-title":"Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations","volume":"57","author":"Funk","year":"2025","journal-title":"Nat Genet"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"<Mutational landscape determines.pdf>","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"<Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.pdf>","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"R10-20261016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2290_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:01:36Z","timestamp":1792152096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2290_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2290_25","relation":{},"ISSN":["1998-4138","0973-1482"],"issn-type":[{"value":"1998-4138","type":"print"},{"value":"0973-1482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}